Re­mem­ber that post-mar­ket­ing tri­al? New study con­firms many drug­mak­ers don’t do them — half drag their feet

Ear­li­er this month Sarep­ta con­firmed to us that the post-mar­ket­ing study the FDA re­quired in their con­tro­ver­sial OK for the Duchenne MD drug Ex­ondys 51 — now on the mar­ket at $1 mil­lion a year — was years be­hind sched­ule. 

But it’s right in line with the in­dus­try norm — which runs from slow to glacial.

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA